Laura uncovered her passion for creating and communicating the scientific story while working in drug discovery at OSI Pharmaceuticals. Since then, Laura has crafted and executed scientific strategy and communication campaigns designed to shift beliefs and behaviors in the marketplace. Today at rareLife, Laura partners with clients to drive success through the translation of complex science and marketplace dynamics into strategic vision and tactical execution.
Laura has a special interest in rare diseases and the patient and caregiver experience. In addition to her 10-year professional experience in rare diseases, Laura serves as a pro bono communications strategist for the National MPS Society, a rare disease patient organization. Laura believes that achieving success in rare diseases requires rareForward thinking and a high-performance ecosystem with a shared vision and commitment to transforming the patient experience.
rareLife solutions specializes in 3 elements critical to the successful development of treatments for rare diseases: collaboration, science and technology. We offer integrated consulting services and software and platform as a service solutions for advocacy groups, pharmaceutical and device companies, medical and research centers, and professional healthcare associations. Our community building technology - onevoice.world - is customized with the guidance of patients, advocates and caregivers from the community for which the platform serves - see www.onescdvoice.com developed by and for the sickle cell community.We look for the solution where it may not already exist, we build things to fill voids, we listen, watch and learn for insights and opportunities to truly be of service to people impacted by rare disease. We vision new ideas (the easy part) and roll up our sleeves to implement them (the really hard part). We collaborate and join forces with those companies, institutions and organizations who are also seeking better treatments and services for the historically underserved rare disease communities.